Henderson Morley still in talks to divest ICVT asset
This article was originally published in Scrip
Executive Summary
Henderson Morley has said it remains confident that its negotiations with KMS Therapeutics will result in a sale of its ICVT (Ionic Contra Viral Therapy) portfolio, as agreed in the letter of intent (LOI) signed earlier this year by KMS. However, Henderson Morley will remain in discussions with the unnamed non-European company that signed a previous LOI concerning ICVT in October last year. These discussions will continue until such time as the sale of ICVT is concluded, Henderson Morley noted.